Aripiprazole and trazodone cause elevations of 7-dehydrocholesterol in the absence of Smith-Lemli-Opitz Syndrome

被引:30
作者
Hall, Patricia [1 ]
Michels, Virginia [2 ]
Gavrilov, Dimitar [1 ]
Matern, Dietrich [1 ]
Oglesbee, Devin [1 ]
Raymond, Kimiyo [1 ]
Rinaldo, Piero [1 ]
Tortorelli, Silvia [1 ]
机构
[1] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Rochester, MN USA
[2] Mayo Clin, Coll Med, Dept Med Genet, Rochester, MN USA
关键词
7-dehydrocholesterol; Smith-Lemli-Opitz Syndrome; Aripiprazole; Trazodone; Cholesterol; DRUGS ACTIVATE SREBP; PHARMACOKINETICS; BIOSYNTHESIS; PATHOGENESIS; CHOLESTEROL; DIAGNOSIS;
D O I
10.1016/j.ymgme.2013.04.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Screening for Smith-Lemli-Opitz Syndrome (SLOS) using elevated 7-dehydrocholesterol (7DHC) as a marker is sensitive, but not always specific. Elevations of 7DHC can be seen in patients who do not have a defect in 7-dehydrocholesterol reductase. These results have often been attributed to medication artifacts, but specific causes have not been well reported. We examined the medical records of patients with elevated 7DHC to determine if they had been diagnosed with SLOS; and if they had not, to identify any common medications that may have caused the elevations. We found three individuals who were affected with SLOS, and 22 with elevated 7DHC in the absence of SLOS. Seven of these individuals underwent molecular testing which showed no mutations, while the other 15 were excluded based on clinical findings and other testing. The medication history of these individuals revealed aripiprazole and trazodone as common medications to all the false positive results. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:176 / 178
页数:3
相关论文
共 14 条
  • [1] Pharmacokinetics and metabolism update for some recent antipsychotics
    Caccia, Silvio
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (07) : 829 - 846
  • [2] Smith-Lemli-Opitz syndrome
    DeBarber, Andrea E.
    Eroglu, Yasemen
    Merkens, Louise S.
    Pappu, Anuradha S.
    Steiner, Robert D.
    [J]. EXPERT REVIEWS IN MOLECULAR MEDICINE, 2011, 13 : e24
  • [3] Dehart DB, 1997, AM J MED GENET, V68, P328, DOI 10.1002/(SICI)1096-8628(19970131)68:3<328::AID-AJMG15>3.0.CO
  • [4] 2-V
  • [5] Cognitive and behavioral aspects of Smith-Lemli-Opitz syndrome
    Diaz-Stransky, Andrea
    Tierney, Elaine
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2012, 160C (04) : 295 - 300
  • [6] Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?
    Ferno, J
    Raeder, MB
    Vik-Mo, AO
    Skrede, S
    Glambek, M
    Tronstad, KJ
    Breilid, H
    Lovlie, R
    Berge, RK
    Stansberg, C
    Steen, VM
    [J]. PHARMACOGENOMICS JOURNAL, 2005, 5 (05) : 298 - 304
  • [7] Kelley R.I., 2001, METABOLIC MOL BASES
  • [8] DIAGNOSIS OF SMITH-LEMLI-OPITZ SYNDROME BY GAS-CHROMATOGRAPHY MASS-SPECTROMETRY OF 7-DEHYDROCHOLESTEROL IN PLASMA, AMNIOTIC-FLUID AND CULTURED SKIN FIBROBLASTS
    KELLEY, RI
    [J]. CLINICA CHIMICA ACTA, 1995, 236 (01) : 45 - 58
  • [9] Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management
    Porter, Forbes D.
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2008, 16 (05) : 535 - 541
  • [10] PRESKHORN SH, 1993, J CLIN PSYCHIAT, V54, P55